Evidence map›Paper›PMID 28097390›Full record

ReviewJournal of molecular medicine (Berlin, Germany)2017

A role of PLC/PKC-dependent pathway in GLP-1-stimulated insulin secretion.

Makoto Shigeto, Chae Young Cha, Patrik Rorsman, Kohei Kaku

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of molecular medicine (Berlin, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. APurinergic signalling · 2025
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Makoto ShigetoOxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Old Road, Oxford, OX3 7LE, UK. shigeto@med.kawasaki-m.ac.jp.
Chae Young ChaOxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Old Road, Oxford, OX3 7LE, UK.
Patrik RorsmanOxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Old Road, Oxford, OX3 7LE, UK.
Kohei KakuDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan.
Churchill Hospital · GBKawasaki Medical School · JPOxford Centre for Diabetes, Endocrinology and Metabolism · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

Glucagon-like peptide-1 (GLP-1) is an endogenous glucose-lowering hormone and GLP-1 receptor agonists are currently being used as antidiabetic drugs clinically. The canonical signalling pathway (including cAMP, Epac2, protein kinase A (PKA) and K

Indexed as

AnimalsCalcium ChannelsCyclic AMPGlucagon-Like Peptide 1GlucoseHumansHypoglycemic AgentsInsulinInsulin-Secreting CellsKATP ChannelsProtein Kinase CSignal TransductionTransient Receptor Potential ChannelsTRPM Cation ChannelsType C PhospholipasesCalcium ChannelsCyclic AMPGlucagon-Like Peptide 1GlucoseHypoglycemic AgentsInsulinKATP ChannelsProtein Kinase CTransient Receptor Potential ChannelsTRPM Cation ChannelsType C PhospholipasesGLP-1Insulin secretionKATP channelPKAPKCTRP channels

Identifiers

PMID28097390
OpenAlexW2575775760

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.